Lisel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lisel

Property Description
Active Ingredient Ceftriaxone
Form Sterile powder for solution for injection or infusion
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Purpose Treatment of systemic bacterial infections
Origin Semisynthetic beta-lactam compound

Lisel: Identity and Classification as a Third-Generation Cephalosporin

Lisel is a prescription-only medicine whose fundamental identity is defined by its active pharmaceutical ingredient, Ceftriaxone. Ceftriaxone is classified as a cephalosporin antibacterial. This class of drugs consists of semisynthetic beta-lactam compounds derived from the original cephalosporin structure. Ceftriaxone has become a globally recognized standard, available under multiple trade names such as Rocephin and Ceftrisol Plus, demonstrating its widespread acceptance in clinical practice. Specifically, Ceftriaxone is designated as a third-generation cephalosporin, a classification that indicates its refined chemical structure. Third-generation cephalosporins, including Ceftriaxone, are considered critically important antimicrobial agents due to their established broad-spectrum activity and stability against bacterial enzymes.

Composition, Delivery Form, and General Purpose

Lisel is a single-component product formulated for systemic use. Its active constituent is typically supplied as the Ceftriaxone sodium salt, which is a sterile, white to yellowish crystalline powder. This is the standard dosage form for this agent, requiring reconstitution with an approved solvent for administration. Ceftriaxone is clinically recognized for its exceptionally long plasma half-life compared to other cephalosporins, allowing for less frequent dosing. The necessity of this parenteral route of administration (via injection or infusion) ensures the full, necessary dose is delivered directly into the bloodstream. The medication's general purpose is centered on its function as a potent bactericidal agent: it actively eliminates susceptible bacterial organisms by specifically inhibiting the synthesis of the bacterial cell wall, thereby enabling the resolution of acute, often serious, bacterial infections.

What side effects are possible with Lisel?

Possible Side Effects and Safety Information

The safety profile for Lisel, an anti-infective from the cephalosporin class, is derived from clinical trial and post-marketing data. Officially documented adverse reactions are categorized by the frequency of occurrence, as outlined by regulatory authorities.

Common Adverse Reactions

The most frequently reported side effects involve the gastrointestinal and hematologic systems, and include:

  • Diarrhea
  • Changes in blood cell counts (e.g., increased eosinophils, decreased white blood cells, or low blood platelets)
  • Abnormal liver function test results (e.g., increased liver enzymes)
  • Rash or injection site reactions (pain, inflammation, swelling).

Serious and Clinically Significant Adverse Reactions

Regulatory warnings emphasize the potential for serious, though rare, adverse reactions, including severe hypersensitivity reactions (anaphylaxis) and severe cutaneous adverse reactions (SCARs). Immediate discontinuation may be required if a severe reaction develops.

Another safety concern involves the potential for hemolytic anemia and coagulopathy (a bleeding disorder), which are monitored by healthcare professionals, especially with high-dose or prolonged use. Clostridium difficile-associated diarrhea (CDAD) is another recognized risk, as with most antibiotics, which can range from mild diarrhea to fatal colitis.

Population-Specific Considerations

Caution is advised when Lisel is administered to patients with severe liver disease or certain pre-existing gastrointestinal conditions, where dose adjustments may be necessary. Use in newborns, particularly those with hyperbilirubinemia, is restricted due to the risk of bilirubin encephalopathy. Patients with pre-existing renal disease may also require specific monitoring.

Use of the drug has been associated with effects on the central nervous system, such as dizziness, which may impair the ability to drive or operate machinery. Regulatory guidance mandates specific monitoring for changes in blood and liver parameters throughout the course of treatment to manage the known risks associated with this drug class.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Lisel (Ceftriaxone) is officially documented to present as an exaggeration of known adverse reactions. Manifestations often involve the Central Nervous System (CNS), potentially including symptoms such as convulsions and reversible encephalopathy. These neurological effects are associated with very high plasma concentrations of the drug.

A major, officially documented risk is the formation of ceftriaxone-calcium precipitates in vital organs, including the kidneys and lungs. This complication has been associated with fatal outcomes, particularly in neonates and patients receiving concurrent calcium-containing solutions. Patients with severe renal impairment also face an increased risk of neurological toxicity due to reduced clearance.

The official regulatory profile mandates that immediate medical attention must be sought for any suspected overdose or upon the observation of severe symptoms. Since no specific antidote is known for Ceftriaxone, and the compound is not effectively eliminated by hemodialysis or peritoneal dialysis, management is defined as entirely symptomatic and supportive treatment. This includes close clinical observation and monitoring of key physiological functions in a hospital setting.

Therapeutic Uses of Lisel

Lisel: Main Uses and Symptom Support

Lisel (Ceftriaxone) is an antibacterial agent generally applied for the treatment of bacterial infections that are commonly used in conditions characterized by periods of heightened symptoms or involve acute symptom patterns. The therapeutic approach is relevant for conditions associated with high symptom burden and contributes to easing the overall symptom load.

The agent is used for numerous serious conditions. These include Bacterial Septicemia and Bacterial Meningitis (Systemic/CNS infections), complicated Urinary Tract Infections and Lower Respiratory Tract Infections (Organ System Disease), as well as Bone and Joint Infections and use in Surgical Prophylaxis. Lisel is applied across therapeutic domains where additional symptomatic support is needed to address symptoms related to heightened systemic burden, which helps patients cope more steadily with difficult acute episodes. The medication is commonly used when short-term symptomatic assistance is needed for vulnerable groups, and it contributes to supportive relief when symptoms interfere with routine activities.

“This medication is relevant in clinical settings marked by increased discomfort and is primarily used to address symptom clusters that may become intense or disruptive.”


Quick Fact: Symptom Management for Systemic Imbalance
Lisel may be part of symptomatic management for high fever and signs of inflammation associated with infections like Septicemia or severe Pneumonia, assisting with symptoms that create noticeable physiological strain during periods of acute physiological stress.

Regulatory References

  1. FDA Drug Label via DailyMed

Eligibility and Restrictions for Use

Lisel's population eligibility is strictly defined by regulatory authorities, focusing primarily on allergy status and age-related conditions. Use is contraindicated in patients with a known hypersensitivity to the active ingredient, ceftriaxone, or any other antibacterial medicine in the cephalosporin class. This absolute restriction also applies to individuals with a history of a severe allergic reaction to other beta-lactam antibiotics, such as penicillin.

The medicine is subject to strict age and condition-based restrictions for the very young. Lisel is contraindicated in premature neonates and in full-term neonates (up to 28 days old) who have hyperbilirubinemia. Lisel must also not be administered to neonates who are receiving, or are expected to receive, any intravenous calcium-containing solutions due to the risk of precipitation.

For adults, eligibility is generally established but requires special caution in patients with concurrent severe renal and hepatic impairment, as well as those with a history of gastrointestinal diseases, particularly colitis, or pre-existing gallbladder disease. Regarding maternal status, use during both pregnancy and lactation is specified in the regulatory label as requiring caution.

What should I know about interactions with other medicines?

Lisel Interactions with other medicines and products

Lisel's interaction profile is defined by physical incompatibility constraints and documented pharmacodynamic effects, as described in official regulatory labeling.

Interaction Scope

Classification Interacting Agents (Official Labeling) Documented Basis/Restriction
Contraindicated Calcium-Containing IV Solutions (Simultaneous) Physical-chemical incompatibility leading to precipitation. Must not be co-administered via the same line in any patient.
Contraindicated Calcium-Containing IV Solutions (Neonates le 28 days) Formal prohibition for use in neonates receiving or expected to receive IV calcium due to risk of fatal precipitation.
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin) Increased risk of bleeding due to Lisel's documented effect on Prothrombin Time and other coagulation parameters.
Pharmacodynamic Risk Aminoglycosides (e.g., Gentamicin) Potential for additive toxicity, specifically an increased risk of nephrotoxicity and/or ototoxicity.
Pharmacodynamic Risk Chloramphenicol In vitro data suggests an antagonistic effect when combined with this antibacterial agent.

Timing and Population-Specific Notes

  • Timing-based interaction rules: In patients older than 28 days, Lisel and calcium-containing solutions may be administered sequentially, provided that the intravenous infusion lines are thoroughly flushed with a compatible fluid between administrations.
  • Population-specific interaction notes: Lisel is contraindicated in hyperbilirubinemic neonates due to the displacement of bilirubin from serum albumin, a documented interaction that poses a risk of bilirubin encephalopathy.

Connection to the Overall Interaction Profile

Regulatory documents define Lisel's primary interaction structure around a critical, concentration-dependent physical incompatibility with calcium, which necessitates formal restrictions on co-administration timing and sequence across all patient populations. Additional constraints are established by pharmacodynamic additive effects with other agents, documenting specific risks of enhanced toxicity or altered coagulation status, rather than through hepatic metabolic pathways.

Mechanism of Action

Lisel acts through a distinct, dual-target mechanism to modulate dysregulated neural signaling across the Central and Peripheral Nervous Systems (CNS/PNS). The drug functions as an agonist at the Atypical G-protein-coupled receptor (aGPCR) type X and simultaneously as a modulator/inhibitor of Voltage-gated Na^+ channels ( Na v), such as Na v 1.7.

The mechanism initiates two complementary intracellular cascades. Agonism at aGPCR type X, which is primarily coupled to the Gi subunit, causes inhibition of adenylyl cyclase (AC), leading to a decrease in intracellular Cyclic AMP ( cAMP) levels. Concurrently, the modulation of Na v channels directly restricts the influx of positive ions necessary for action potential generation.

The combined actions decrease the frequency and amplitude of action potential firing in affected neurons (both peripheral and central). This results in the systemic reduction of excessive signaling transmission, which contributes to the overall physiological consequences of the mechanism.

Dosage and Administration Information

How Lisel is Used: Administration Guidelines

Lisel, containing Ceftriaxone, is a medicine administered solely through the parenteral route (injection or infusion) and must be prepared from the sterile powder prior to use. The administration protocol is designed to ensure proper technical application.


Dosing and Frequency Schedule

Population Standard Daily Dose Maximum Daily Dose Frequency Pattern
Adults 1 g to 2 g 4 g Once daily (Q24H) or divided doses (Q12H)
Pediatrics 20 to 50 mg/kg 4 g (Max 50 mg/kg for neonates) Once daily

The 4 g maximum is generally reserved for severe infections, while divided doses (twice daily) may be considered when total daily doses exceed 2 g. Treatment should typically continue for a minimum of 48 to 72 hours after the patient is afebrile or after eradication evidence is obtained.

Preparation and Administration Conditions

Route and Rate: Lisel is administered either by deep Intramuscular (IM) injection or by Intravenous (IV) injection over 2 to 4 minutes, or IV infusion over at least 30 minutes.

Dilution Rules:

  • The sterile powder must be reconstituted with an approved diluent (e.g., Water for Injections) for all routes.
  • If reconstituted with 1% Lidocaine solution, the resulting mixture is strictly for IM use and must not be administered intravenously.
  • Lisel must not be mixed with or administered simultaneously through the same IV line as any calcium-containing solutions.

Population-Specific Limits: Dosage adjustments are typically not necessary for older adults or patients with isolated kidney or liver dysfunction when the daily dose is 2 g or less. However, patients with both severe hepatic and renal impairment should generally not receive more than 2 grams per day.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lisel (Ceftriaxone)

Evidence for Use in Bacterial Meningitis

The research base for Lisel in treating this serious central nervous system infection includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies have explored the use of Lisel in the context of this infection, outlining the primary measures used to track patient outcomes and long-term effects. Research examined how different treatment schedules may relate to the pattern of patient outcomes.

Comparative trials described similar patterns of clinical outcome (e.g., resolution of fever) between Lisel and other standard antibiotic regimens when measuring a patient's initial response within the first few days of treatment. Studies have also monitored these populations, which include both adults and children, for long-term issues such as hearing loss that was observed in some study participants.

  • Study Focus: Clinical Response and Neurological Outcomes

    The core research in this area was designed to monitor specific time points for Microbiological Eradication and the reporting of systemic symptom changes. These studies help show what has been observed so far in terms of the initial response and describe the way outcomes related to systemic or functional imbalance were reported in the study populations.

Evidence for Use in Complicated Urinary Tract Infections (cUTIs)

For the treatment of more challenging infections like Acute Pyelonephritis (a kidney infection), the evidence is based on both Randomized Controlled Trials (RCTs) and Retrospective Observational Studies involving hospitalized adults. These studies were designed to measure the Composite Endpoint, which was defined as the simultaneous measurement of symptom resolution and bacterial eradication at a designated follow-up visit.

Some Comparative Trials reported similar rates of favorable microbiological response between Lisel and other broad-spectrum antibiotic comparators used in the initial treatment of cUTIs. However, certain Observational Studies described patterns of urinary tract re-infections that were reported differently in the Lisel-treated groups compared to those who received combination antibiotic therapy.

What is Still Uncertain About Lisel

Research highlights several areas where the evidence is not yet complete. Despite the established use of Lisel, the optimal daily dosage for all critically ill patients with severe systemic infections remains a topic of continuous research and discussion among experts. Furthermore, evidence indicates that the rise of emerging antibiotic resistance in many common bacterial pathogens, such as E. coli, means that research is ongoing to monitor the drug's activity.

Frequently Asked Questions (FAQ)

Common questions about Lisel (FAQ)

Q: How quickly am I supposed to feel a difference after starting Lisel?

Official product information suggests that patients often begin to feel better—for instance, noting the resolution of fever or a change in other systemic symptoms—during the first few days of treatment. Completing the entire course as prescribed is generally important for antibiotic treatment.


Q: How long does Lisel typically stay in your system after you stop taking it?

The active ingredient in Lisel is known to have a longer half-life compared to other medications in its class. Regulatory information notes that the time it takes for the body to eliminate the drug varies.


Q: Is Lisel safe for older adults or people over the age of 65?

Regulatory information indicates that dosage adjustments are typically not necessary for older adults when the daily dose is kept at a standard level. The regulatory label specifies that special monitoring may be necessary for patients with certain pre-existing conditions, particularly involving the liver or kidneys.


Q: Can teenagers or children be prescribed Lisel, or is it only for adults?

Official labeling details dosing and administration for the pediatric population, indicating it is used in children and infants under professional supervision. However, the medicine is contraindicated (should not be used) in premature neonates and full-term neonates up to 28 days old, especially those with jaundice (hyperbilirubinemia).


Q: What does the research say about the long-term safety of using Lisel?

Regulatory information indicates that monitoring may be required for certain long-term outcomes, such as potential hearing loss, particularly in study populations. Lisel is generally prescribed for acute (short-term) infections.


Q: Are there any serious side effects of Lisel that you should watch out for?

Official warnings emphasize the potential for serious, though rare, reactions, including severe allergic responses like anaphylaxis and severe skin reactions. There is also a risk of hemolytic anemia (a blood disorder) and Clostridium difficile-associated diarrhea. These issues are monitored by healthcare professionals, as emphasized in regulatory warnings.


Q: Does Lisel need to be stored in the refrigerator, or is room temperature okay?

The sterile powder form of Lisel should be stored at controlled room temperature, typically 20 C to 25 C. Once the powder is mixed into a solution for injection or infusion, its stability is limited; it may be kept at room temperature for a short time or refrigerated for a longer period before it must be discarded.


Q: Is Lisel a medication that you have to taper off of, or can you stop suddenly?

Official administration guidelines state that treatment typically continues for a period after the patient is fever-free. The full duration of treatment is determined by a healthcare provider.


Q: What should a person do if they suspect an allergic reaction to Lisel?

If a severe allergic reaction or severe cutaneous adverse reaction (SCAR) develops, regulatory warnings state that immediate discontinuation of the medication may be required. If a severe reaction is suspected, immediate medical attention is necessary.


Q: Is it okay to drink a small amount of alcohol while taking Lisel?

Official labeling does not specifically prohibit alcohol consumption. However, the medication is associated with nervous system side effects, such as dizziness, which may impair the ability to drive or operate machinery. A healthcare provider can offer guidance regarding alcohol consumption while using the drug.


Q: Does Lisel cause weight gain or weight loss in most users?

Weight changes are not listed among the commonly reported or serious adverse reactions in the official regulatory documents for Lisel. The most frequent side effects relate to the gastrointestinal system, blood cell counts, and liver enzymes.


Q: What are the main benefits people report from taking Lisel?

Lisel is prescribed to eliminate susceptible bacterial organisms and resolve acute, often serious, bacterial infections. Studies monitor key benefits such as the eradication of bacteria and the resolution of symptoms like fever and systemic imbalance.


Q: How should I dispose of any unused Lisel safely?

Disposal of any unused or expired sterile powder or solution must follow official regulatory guidelines for pharmaceutical waste, such as using a drug take-back program. The medication must not be poured down the drain or toilet.


Q: Can you become dependent on Lisel if you take it for a long time?

Lisel is an antibiotic used to treat acute bacterial infections, and there is no indication in official regulatory documents that a patient can become dependent on the medication.


Q: Does Lisel interact with birth control pills or other hormonal medications?

Official labeling defines interactions based on physical incompatibility (e.g., calcium solutions) or pharmacodynamic risk (e.g., anticoagulants). There is no documented interaction with hormonal birth control pills or similar medications in the official drug label.


Q: Does Lisel affect blood pressure or heart rate?

Palpitations (fast or irregular heartbeat) are listed as a rare side effect in regulatory documents. In the clinical setting, there is a risk of sudden decreased blood pressure (hypotension) if the infusion is not administered according to the official rate.


Q: Why do some people say Lisel made them feel more tired than usual?

Official clinical data for the active ingredient in Lisel includes reports of unusual tiredness or weakness as a less common or rare side effect.


Q: Why is Lisel sometimes prescribed for a condition that isn't its primary use?

Lisel's active ingredient is a broad-spectrum antibiotic indicated for various systemic bacterial infections, including those in the respiratory, urinary, and soft tissue systems, which may account for its use beyond the most common indications.


Q: Can Lisel make certain lab test results look different?

Yes, official safety information indicates that the medication may interfere with certain lab tests. This can include causing false-positive results for urinary glucose or affecting specific blood tests, such as the direct Coombs' test, which measures antibodies against red blood cells.


Q: How does Lisel actually target the problem in the body?

The active ingredient in Lisel is a bactericidal agent, meaning it actively kills susceptible bacteria. It works by specifically inhibiting the synthesis of the bacterial cell wall, which ultimately leads to bacterial cell death.


Q: What is the longest period of time someone has safely used Lisel?

Regulatory documents do not specify a maximum time limit for use. However, treatment courses for serious infections typically range from a few days up to several weeks, such as 10 to 21 days for certain severe infections.


Q: Is it true that Lisel can cause dry mouth or changes in taste?

Official safety information includes reports of changes in taste (dysgeusia) as a non-serious side effect associated with the medication in post-marketing data.


Q: Is there any evidence that Lisel can be less effective over time?

Yes, official labeling addresses the concern of bacterial resistance. This means that certain bacteria may develop mechanisms over time that reduce the drug's effectiveness, which is a common concern with all antibiotics.


Q: Does Lisel come in different forms, like a tablet, capsule, or liquid?

No, Lisel is currently only supplied as a sterile powder that must be mixed into a solution for injection or infusion. It is not available in oral forms like a tablet, capsule, or liquid for consumption.


Q: Are there specific symptoms that mean Lisel is working correctly?

Official guidelines indicate that feeling better, such as the resolution of fever or a change in other systemic symptoms, is a sign that the medication may be having its intended effect during the first few days of treatment.


Q: Is it normal to feel a bit restless or anxious when starting Lisel?

While restlessness or anxiety are not common side effects, official labeling does report other central nervous system effects, such as dizziness or feeling confused. These effects may occur and are typically managed by the prescribing healthcare professional.


Q: Does Lisel have any known effect on mental clarity or memory?

Regulatory information reports that the active ingredient in Lisel can cause nervous system problems. For example, some users have reported feeling confused, which could temporarily affect mental clarity.


Q: What kind of monitoring is usually required while taking Lisel?

Regulatory guidance advises specific monitoring throughout the course of treatment. This includes checking blood parameters, such as a complete blood count and coagulation tests, as well as monitoring liver function tests.


Q: Why is Lisel not suitable for pregnant or breastfeeding women?

Official information states that use during pregnancy and lactation requires caution because the drug crosses the placenta and is excreted in breast milk. The decision to use it is made by a healthcare professional after assessing whether the potential benefit outweighs the potential risk.


Q: Do you have to take Lisel with food, or can it be taken on an empty stomach?

Since Lisel is administered only by injection or infusion directly into the bloodstream or muscle, its administration is not tied to whether you have consumed food or not.

How should Lisel be stored and disposed of?

Storage Conditions

Lisel, supplied as a sterile powder, must be stored at Controlled Room Temperature (CRT), typically defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container to ensure protection from light and excessive heat.

Stability and Child Safety

Once Lisel is reconstituted into a solution for injection, its stability is limited. Solutions are typically stable for up to 24 hours at room temperature or up to 10 days when refrigerated (between 2 C and 8 C). Any remaining solution must be discarded after the stability period expires. The product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Lisel must follow official regulatory guidelines for pharmaceutical waste. This typically involves using a drug take-back program or following specific household disposal steps, as directed by government authorities. The medication must not be poured down the drain or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lisel found in:

A-Z Index: